Resources, guidance and updates from the GDP community.
2025 Conferences
Supply Chain Resilience in the UK Pandemic The 2025 UK GDP Association Annual Conference brought forward a wide range of perspectives on resilience, regulation, and best practice, but few sessions captured the realities of large-scale crisis...
2025 Conferences
Repercussions of the Windsor Framework by Natasha Long, Fusion Pharma LimitedDelegates at the 2025 UK GDP Association CIC Annual Conference heard from a wide range of industry specialists from across the pharmaceutical, and healthcare sectors. Among...
2025 Conferences
Regulatory Agencies in UK and Ireland: Spot the Difference At the 2025 UK GDP Association Annual Conference, one session that drew strong interest from Responsible Persons, compliance leads, and distribution professionals was “MHRA and HPRA – Spot...
2025 Conferences
The 2025 UK GDP Association Annual Conference - were you there? The 2025 UK GDP Association Annual Conference brought together professionals at the heart of Good Distribution Practice (GDP), regulatory compliance, quality assurance and...
2025 Conferences
Medicine Shortages and Banned Exports by Graham Stewart, DHSC At the 2025 UK GDP Association CIC Annual Conference, attendees heard from a wide range of experts working across regulation, supply chain management and pharmaceutical quality. Each...
2025 Conferences
Understanding ARMPs IMPS and Clinical Trials by Steve Mannering (Thermo Fisher Scientific)Our 2025 UK GDP Association Conference brought together some of the most respected leaders shaping the future of pharmaceutical quality and compliance. In this...
2025 Conferences
UK Medical Cannabis Progress, and the challenges to come The second speaker session on day one of the 2025 UK GDP Association Annual Conference came from Nik Sanghara, Director of Canna Strategy Ltd, who provided delegates with a thorough,...
2026 M&DP Conference
Question 8: Does having a competent RP give you a competitive edge? Victoria Emerton (VE) – Making and Distributing Pharmaceuticals: “Final question, does having an RP give you a competitive edge? Obviously, you need an RP to be compliant and...
2026 M&DP Conference
Question 7: Will you be discussing what a Gold Standard Audit trail looks like when it comes to proving that a licence holder has fulfilled their duty? Victoria Emerton (VE) – Making and Distributing Pharmaceuticals: “You’ve mentioned the Gold...
2026 M&DP Conference
Question 6: How do you plan to address the Licence Holders role in protecting the RPs independence in relation to GDP requirements and meeting commercial targets? Victoria Emerton (VE) – Making and Distributing Pharmaceuticals: “I want to talk...
2026 M&DP Conference
Question 5: Are there specific warning signs that Licence Holder oversight is failing? Victoria Emerton (VE) – Making and Distributing Pharmaceuticals: “So, we’re going to move on to ‘red flags’ in terms of oversight. I think this is quite a...
2026 M&DP Conference
Question 4: What are the strategies for Licence Holders to verify an RP’s competence when they aren’t in touch with their RP very often? Victoria Emerton (VE) – Making and Distributing Pharmaceuticals: “You’ve talked about how, basically, you...
Join the UK GDP Association to access exclusive member-only articles, early event access, and professional development resources.